BioHarvest wins $1.4M Israel innovation grant

BioHarvest Sciences Inc. reported that the Israel Innovation Authority approved a 4.33 million NIS (approximately USD $1.4 million) grant, structured as a non-dilutive, zero-interest loan.

Rhea-AI Filing Summary

BioHarvest Sciences Inc. reported that the Israel Innovation Authority approved a 4.33 million NIS (approximately USD $1.4 million) grant, structured as a non-dilutive, zero-interest loan. Repayment is contingent on predefined commercial milestones and is expected to come solely from revenues generated by the funded project, with no equity or equity-linked securities issued.

The funding supports a new research initiative that integrates advanced data science, machine learning, computer vision and high-throughput digital sensing into BioHarvest’s plant cell culture workflows, aiming to shift from trial-and-error to predictive, data-driven optimization and higher active metabolite yields. This is the second Israel Innovation Authority grant to BioHarvest this year, with the first focused on automating the manufacturing facility and the new grant targeting the early-stage R&D pipeline through predictive AI, together spanning discovery through to large-scale production.

Key Figures

IIA grant amount: 4.33 million NIS Approximate USD value: USD $1.4 million Number of IIA grants in 2026: 2 +2 more

5 metrics

IIA grant amount 4.33 million NIS Approved non-dilutive grant from Israel Innovation Authority to fund a new research initiative

Approximate USD value USD $1.4 million Approximate value of the 4.33 million NIS Israel Innovation Authority grant

Number of IIA grants in 2026 2 This marks the second grant BioHarvest has received from the Israel Innovation Authority this year

Date of material change July 15, 2026 Date specified as the material change and news release date

Investor relations phone 604 622-1187 Contact number for David Ryan, Secretary and VP, Investor Relations

Key Terms

non-dilutive funding, plant cell culture, bioinformatics, chemo-informatics, +2 more

6 terms

non-dilutive funding financial

"This non-dilutive funding will support a new research initiative"

Non-dilutive funding is money a company raises that does not require issuing new shares or reducing existing owners’ percentage ownership, such as grants, certain loans, contract revenue, or licensing deals. It matters to investors because it lets a company finance growth or research without shrinking shareholder stakes or changing control, much like topping up a car’s gas tank instead of selling part of the car to pay for the trip.

plant cell culture technical

"accelerating its plant cell culture programs"

A plant cell culture is a laboratory method that grows plant cells, tissues, or tiny plant fragments in controlled liquid or gel trays instead of in soil, like keeping a miniature garden under glass. Investors care because it lets companies produce plant-based compounds—such as flavors, pigments, medicines or active ingredients—more reliably and at scale, reducing reliance on crops, lowering supply-chain risk, and creating opportunities for recurring revenue and intellectual property.

bioinformatics technical

"by combining bioinformatics, chemo-informatics and artificial intelligence"

The use of computer tools and data analysis to organize and interpret large biological datasets, such as DNA, protein or patient information. It matters to investors because it speeds up research, lowers development costs and helps identify promising drug targets, diagnostics or personalized treatments—think of it as using GPS and analytics to find the fastest, most reliable route through vast amounts of lab data.

chemo-informatics technical

"by combining bioinformatics, chemo-informatics and artificial intelligence"

A field that uses computers, databases and statistical methods to organize, analyze and model chemical and molecular information. It turns complex chemical data into searchable patterns, predictions and visual maps—like using GPS and analytics to navigate a vast landscape of possible molecules. It matters to investors because it can speed drug discovery, reduce lab costs and highlight promising compounds earlier, affecting development timelines, budgets and potential returns.

high-throughput digital sensing technical

"computer vision and high-throughput digital sensing directly into BioHarvest’s workflows"

commercial milestones financial

"Repayment is contingent upon the achievement of certain predefined commercial milestones"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What material change did BioHarvest Sciences (BHST) report on July 15, 2026?

BioHarvest Sciences (BHST) reported approval of a 4.33 million NIS (about USD $1.4 million) grant from the Israel Innovation Authority, structured as a non-dilutive, zero-interest loan to support a new predictive AI-driven plant cell culture research initiative.

How large is the Israel Innovation Authority grant to BioHarvest Sciences (BHST)?

The Israel Innovation Authority approved a 4.33 million NIS grant for BioHarvest Sciences (BHST), described as approximately USD $1.4 million. The funding will back advanced data science and AI integration into the company’s plant cell culture research and development workflows.

Is the new Israel Innovation Authority funding dilutive to BioHarvest (BHST) shareholders?

The funding is described as non-dilutive. It is provided as a zero-interest loan, with repayment tied to commercial milestones and expected only from revenues of the funded project, and no equity or equity-linked instruments were issued in connection with the grant.

What will BioHarvest Sciences (BHST) use the new IIA grant for?

BioHarvest will use the new funding to build a predictive, data-driven plant cell culture platform, integrating bioinformatics, chemo-informatics, machine learning, computer vision and high-throughput digital sensing to forecast propagation success and maximize active metabolite and bioactive yields.

How does this second IIA grant differ from the first grant to BioHarvest (BHST) in 2026?

The first 2026 IIA grant focused on scaling the manufacturing facility with industrial automation and machine learning. The second grant targets early-stage R&D, using predictive AI to transform laboratory discovery, together linking intelligent discovery with autonomous commercial production.

What are the repayment terms of the Israel Innovation Authority grant to BioHarvest (BHST)?

The grant is structured as a non-dilutive, zero-interest loan. Repayment is contingent on achieving predefined commercial milestones and is expected to be made solely from future revenues generated by the specific project funded by the Israel Innovation Authority.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/15/2026 - 05:57 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission file number: 001-42389

BIOHARVEST SCIENCES INC.

(Exact name of Registrant as specified in its charter)

Not applicable

(Translation of Registrant’s name into English)

1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SUBMITTED HEREWITH

Exhibits:

Exhibit	Description
99.1	Material Change Report dated July 15, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOHARVEST SCIENCES INC.
	(Registrant)
Date: July 15, 2026	/s/ David Ryan
	Name: David Ryan
	Title: Vice-President, Investor Relations & Secretary

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1.Name and Address of Company 

BIOHARVEST SCIENCES INC.

Suite 1140 – 625 Howe Street

Vancouver, BC, V6C 2T6

(the “Company” or “BioHarvest”)

Item 2.Date of Material Change 

July 15, 2026.

Item 3.News Release 

The news release (the “News Release”) was issued on July 15, 2026 and disseminated by Newsfile Corp.

Item 4.Summary of Material Change 

The Company announced a US $1.4M grant from the Israel Innovation Authority.

Item 5.Full Description of Material Change 

The Company announced the Israel Innovation Authority (IIA) has approved a 4.33 million NIS (approximately USD $1.4 million) grant. This non-dilutive funding will support a new research initiative at BioHarvest integrating advanced data science, machine learning, computer vision and high-throughput digital sensing directly into BioHarvest’s biological development workflows, thereby accelerating its plant cell culture programs.

BioHarvest’s new approved research initiative focuses on moving plant cell culture from traditional empirical trial-and-error methods to a highly predictable, data-driven optimization framework. Specifically, by combining bioinformatics, chemo-informatics and artificial intelligence, the platform will systematically predict the success of plant cell propagation and dramatically maximize active metabolite yields.

Specifically, the program will accelerate the development of BioHarvest's advanced computational discovery engine. This platform integrates proprietary predictive machine learning models with real-time digital sensing to rapidly identify optimal pathways and maximize bioactive yields across diverse plant species. Supported by secure, domain-specific scientific knowledge bases, these new capabilities will streamline early-stage R&D, transforming how complex plant-based compounds are forecasted, monitored, and scaled.

This marks the second grant BioHarvest has received from the Israel Innovation Authority this year. While the first grant was dedicated to scaling the manufacturing facility by integrating industrial automation and machine learning on the factory floor, this second grant is strictly focused on transforming the early-stage R&D pipeline through predictive AI. Together, these two distinct yet highly complementary initiatives fuel a technological transformation across the company - bridging the gap between intelligent, data-driven laboratory discovery and high-volume, autonomous commercial production.[IG1.1]

The grant was provided by the Israel Innovation Authority in the form of a non-dilutive, zero-interest loan. Repayment is contingent upon the achievement of certain predefined commercial milestones and is expected to be made solely from future revenues generated by the funded project. No equity or equity-linked instruments were issued in connection with the grant.

About the Israeli Innovation Authority (IIA)

The Israeli Innovation Authority is a government entity dedicated to fostering Israel’s innovation ecosystem by supporting companies across all stages of technology development, from early research through industrial deployment. For more information, visit https://innovationisrael.org.il/en/.

Item 6.Reliance on Subsection 7.1(2) of National Instrument 51-102 

Not applicable.

Item 7.Omitted Information 

None.

Item 8.Executive Officer 

For further information, please contact:

David Ryan

Secretary and VP, Investor Relations

604 622-1187

Item 9.Date of Report 

July 15, 2026.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 MATERIAL CHANGE REPORT DATED JULY 15, 2026 12.3 KB